EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Early Development of Ocadusertib, a Selective Receptor‐Interacting Serine/Threonine‐Protein Kinase 1 Inhibitor

Simon J Shaw iD, Vanessa C Taylor iD, Jonathan T Sims iD, Stephen Ho, Chrystelle Lamagna iD, Lucy Yan, Nicholas C Reising, Andrew Chow iD, Eric P Hanson iD, Andrew C Vendel iD, Daniel J Dairaghi, Esteban S Masuda iD

Clinical and Translational Science · 2026-03 · 19 (3)

DOI: 10.1111/cts.70519 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, online erschienen am 06.03.2026. Verfasst von Simon J Shaw und 11 weiteren Autor:innen. Beteiligte Einrichtung: Rigel Pharmaceuticals, Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Pyrazoles, Receptor-Interacting Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company, Rigel Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Receptor‐interacting serine/threonine‐protein kinase 1 (RIPK1) inhibitors are being investigated for chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Ocadusertib is a potent and selective allosteric inhibitor of RIPK1 and is currently being studied in clinical trials. Here, we present data on the development of ocadusertib, including preclinical studies and pharmacokinetic, safety, and target engagement results from phase 1 trials. Preclinically, ocadusertib inhibited RIPK1 enzymatic activity with high potency (half‐maximal inhibitory concentration [IC 50 ] = 12–38 nM) and inhibited necroptotic responses in multiple cell‐based assays. Ocadusertib was highly selective for RIPK1, showing no significant inhibition of more than 100 other kinases representative of the full kinome. In mouse studies, ocadusertib treatment prevented RIPK1‐dependent hypothermia in response to tumor necrosis factor (TNF) challenge and significantly reduced disease severity in a model of chronic proliferative dermatitis. In a first‐in‐human study of ocadusertib in healthy participants, single oral doses exhibited linear pharmacokinetics and dose‐proportional exposure, with a time to maximum concentration of 1–4 h and a half‐life of 13–15 h. Steady state was attained at 4–6 days after multiple once‐daily dose administrations. Ocadusertib was well tolerated, with no deaths, serious adverse events, or significant treatment‐emergent adverse events reported. In a phase 1, double‐blind, randomized, multiple‐dose study in healthy participants, greater than 90% RIPK1 target engagement was achieved at Day 14 with ocadusertib treatment. Taken together, these findings support further assessment of ocadusertib for the treatment of chronic inflammatory diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsPyrazolesReceptor-Interacting Protein Serine-Threonine KinasesAdultAnimalsFemaleHumansMaleMiceDisease Models, AnimalDouble-Blind MethodDrug Evaluation, PreclinicalOxazepinesTriazoles

Stichwörter der Autor:innen

RIPK1clinical trialshealthy subjectsinhibitorspharmacokineticsphase 1preclinicalsafety

Substanzen

GSK2982772Protein Kinase InhibitorsPyrazolesReceptor-Interacting Protein Serine-Threonine KinasesRIPK1 protein, humanOxazepinesTriazoles

Autor:innen und Institutionen

  • Rigel Pharmaceuticals, Inc., South San Francisco, California, USA.
  • Immunology Discovery, Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Neuroscience Discovery, Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Immunology Discovery, Eli Lilly and Company, San Diego, California, USA.

ORCID-Profile: Simon J Shaw, Vanessa C Taylor, Jonathan T Sims, Chrystelle Lamagna, Andrew Chow, Eric P Hanson, Andrew C Vendel, Esteban S Masuda

Förderung

  • Eli Lilly and Company
  • Rigel Pharmaceuticals

Zitieren

APA

Shaw, S. J., Taylor, V. C., Sims, J. T., Ho, S., Lamagna, C., Yan, L., Reising, N. C., Chow, A., Hanson, E. P., Vendel, A. C., Dairaghi, D. J., & Masuda, E. S. (2026). Early Development of Ocadusertib, a Selective Receptor‐Interacting Serine/Threonine‐Protein Kinase 1 Inhibitor. Clinical and Translational Science, 19(3). https://doi.org/10.1111/cts.70519

Vancouver

Shaw SJ, Taylor VC, Sims JT, Ho S, Lamagna C, Yan L, et al. Early Development of Ocadusertib, a Selective Receptor‐Interacting Serine/Threonine‐Protein Kinase 1 Inhibitor. Clinical and Translational Science. 2026;19(3). doi:10.1111/cts.70519

BibTeX
@article{Shaw2026,
  author = {Shaw, Simon J and Taylor, Vanessa C and Sims, Jonathan T and Ho, Stephen and Lamagna, Chrystelle and Yan, Lucy and Reising, Nicholas C and Chow, Andrew and Hanson, Eric P and Vendel, Andrew C and Dairaghi, Daniel J and Masuda, Esteban S},
  title = {Early Development of Ocadusertib, a Selective Receptor‐Interacting Serine/Threonine‐Protein Kinase 1 Inhibitor},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {3},
  doi = {10.1111/cts.70519}
}
Kostenlos starten →